Nootropic Peptides

For laboratory and research use only — not for human consumption. All content is educational.
Route hub

Intranasal research peptides

Intranasal administration is the dominant route for small research peptides in cognitive and neurological research. It bypasses first-pass metabolism, avoids gastrointestinal proteolysis, and reaches the CNS along the olfactory and trigeminal nerve pathways at concentrations that are impractical from an oral or standard-parenteral dose. This page collects the peptides on this site with the intranasal tag, explains why the route matters, and points to the deeper mechanistic material.

The route

Why intranasal delivery matters for cognitive peptides

Small peptides face two obstacles when they need to act in the brain: they are rapidly degraded by proteases in plasma and the gut, and they don't cross the blood-brain barrier at concentrations useful for CNS activity. The intranasal route addresses both problems by exploiting anatomical peculiarities of the nasal cavity.

The olfactory epithelium at the roof of the nasal cavity has a unique property: it is the only site in the body where the CNS reaches an external surface. Olfactory sensory neurons project directly into the olfactory bulb, and peptides deposited on or near the olfactory epithelium can reach the CNS along the olfactory nerve and via perineural transport around the trigeminal nerve fibres. The transport avoids systemic circulation and bypasses the blood-brain barrier entirely.

This is why intranasal Semax, Selank, DSIP, and the Khavinson bioregulators produce measurable central effects at doses that would be pharmacologically inactive if given intravenously. The nose-to-brain pathway is a delivery mechanism that specifically favours the pharmacology of small research peptides.

The catalogue

Peptides on this site administered intranasally

Cognitive Enhancement

Semax

A synthetic heptapeptide analogue of ACTH(4-10) developed in Russia for cognitive enhancement, neuroprotection, and stroke recovery research.

Anxiolytic / Mood

Selank

A synthetic heptapeptide analogue of tuftsin developed for anxiolytic and immunomodulatory research, with measurable effects on attention and mood.

Neuroprotection

Pinealon

A short tripeptide bioregulator studied in Russian gerontology research for neuroprotective and anti-ageing effects on the central nervous system.

Cognitive Enhancement

N-Acetyl Semax Amidate

A chemically protected analogue of Semax with N-terminal acetylation and C-terminal amidation, conferring substantially extended half-life and improved potency in research.

Anxiolytic / Mood

N-Acetyl Selank Amidate

Chemically protected analogue of Selank with extended half-life through N-terminal acetylation and C-terminal amidation; same anxiolytic profile as the parent compound with longer duration.

Neurogenesis

Davunetide

An 8-amino-acid ADNP-derived peptide (NAPVSIPQ) evaluated in multiple neurodegenerative disease trials — the flagship clinical-trial peptide in the synaptogenic / neuroprotective family.

Anxiolytic / Mood

Oxytocin (intranasal)

The endogenous nonapeptide 'social bonding' hormone, studied via intranasal delivery for social cognition, anxiety, and trust-related research endpoints — one of the most-researched peptides in cognitive neuroscience.

Cognitive Enhancement

DDAVP (Desmopressin)

A licensed synthetic vasopressin analogue with documented memory-modulation effects — one of the classical vasopressin-family cognitive research peptides with the deepest historical literature.

Neuroprotection

Cortagen

A synthetic tetrapeptide from the Khavinson bioregulator programme (Ala-Glu-Asp-Pro), positioned as a brain-cortex-targeted bioregulator complementing Pinealon and Cortexin.

Neuroprotection

Vesugen

A Khavinson vascular short peptide (Lys-Glu-Asp) targeting vascular-endothelial gene expression, with cerebrovascular research relevance in cognitive-ageing and stroke-recovery contexts.

Neuroprotection

N-Acetyl Epitalon Amidate

A chemically protected analogue of Epitalon with N-terminal acetylation and C-terminal amidation — same pineal-directed pharmacology as parent Epitalon with extended half-life, mirroring the NA-Semax and NA-Selank pattern.

Cognitive Enhancement

DGAVP

A classical De Wied-laboratory vasopressin analogue engineered to preserve memory-relevant central effects while eliminating the pressor effect of parent vasopressin — the reference vasopressin-family cognitive research peptide of the 1970s-80s.

Cognitive Enhancement

MIF-1

A tripeptide originally identified as an inhibitor of melanocyte-stimulating hormone release, with a distinctive research history spanning memory modulation, dopamine-receptor allosteric effects, and Parkinson's-disease-adjacent research applications.

Cognitive Enhancement

TRH (Thyrotropin-releasing hormone)

The endogenous hypothalamic tripeptide that stimulates thyroid-stimulating hormone release, with distinctive research history in cognitive effects, arousal, mood modulation, and neuroprotective applications separated from the primary thyroid-axis pharmacology.

Cognitive Enhancement

Vasopressin

The endogenous nonapeptide antidiuretic hormone with distinctive central memory-modulation effects — the parent compound of the classical vasopressin-family cognitive research programme and the direct hormone from which DDAVP and DGAVP were engineered.

Practical considerations

Administration technique matters for reproducibility

Head positioning

The olfactory epithelium sits at the roof of the nasal cavity, and reaching it requires a specific head position — tilted forward slightly, not backward, so that the solution reaches the upper cavity rather than draining down the throat. Standard upright-with-tilt-back administration deposits most of the dose in the lower respiratory-focused epithelium and misses the olfactory zone.

Dose partition

Standard research protocols distribute the total dose across both nostrils — usually 1–3 drops per nostril, alternating sides between doses if the daily count exceeds two. Single-nostril administration halves the effective delivery surface and produces measurably lower CNS exposure.

Post-dose behaviour

Sneezing or swallowing immediately post-dose degrades the delivery efficiency substantially. Published protocols specify a 30–60 second quiet-breathing window after each drop to allow the solution to be absorbed rather than swept away by mucociliary clearance.

Formulation

Aqueous formulations at physiological pH and near-isotonic salt concentrations are standard. Non-aqueous or non-physiological-pH formulations are irritating and degrade the delivery efficiency by driving reflexive nasal-clearance responses. Most research-grade peptide preparations arrive as lyophilised solid for reconstitution in bacteriostatic water for injection.